JunHe is a leading full-service law firm in China with a proven track record in advising domestic and foreign companies in the life sciences and healthcare sector. With over 30 years of experience, our multidisciplinary team offers expertise in mergers and acquisitions, capital markets, intellectual property, compliance, and dispute resolution. We provide regulatory services for clinical trials and product registrations, IP transaction services, and legal support for corporate finance, compliance, labor, taxation, and dispute resolution. Our unified internal management ensures comprehensive and high-quality services from our cross-sector and cross-regional lawyers.
Recent Major Deals:
- Advised Elpiscience on its Research Collaboration and License Agreement with Astellas
- Advised Grifols in the sale of a 20% equity stake in SRAAS and its strategic alliance with Haier Group and SRAAS
- Advised Usynova in Granting a Global License for KRAS G12D Inhibitors to AstraZeneca
- Assisted Huagai Capital to establish Huagai Medical RMB Fund IV
- Advised Antengene on its Commercialization Partnership with Hansoh Pharma
- Advised ImmuneOnco on its Listing on the HKEx
- Advised Biocytogen on Its Technical Collaboration with Overseas Biopharmaceutical Companies
- Advised Qyuns on its Listing on the Stock Exchange of Hong Kong
